Cardlytics Q2 revenue down 9% YoY to $63.2M; net loss widens; Q3 guidance weak

Cardlytics, Inc.

2025-Q2 EPS reported -$0.43 vs consensus -$0.17 ▼ miss (-159.3%)

Revenue $63.2M, -9% YoY; billings $104M, -6%; adjusted contribution $36.1M, -1%.
Net loss $(9.3)M ($0.18/diluted share) vs $(4.3)M ($0.09) a year ago.
Adjusted EBITDA improved to $2.7M from $(2.3)M; MQUs up 19% to 224.5M.
Q3 guidance: billings $87-95M (-22% to -15%), revenue $52.2-$58.2M, adjusted EBITDA ($2.3M) to $2.7M.
Free cash flow negative $(3.4)M vs $(0.4)M; ACPU fell to $0.14 from $0.16.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.